A Phase III trial miss has hollowed out the share price of Israel-headquartered clinical-stage diabetes specialist Oramed Pharmaceuticals (Nasdaq: ORMP).
The company has been pinning its hopes on the development of an oral formulation of insulin, ORMD-0801, but the failure of the ORA-D-013-1 study has shaken the firm’s prospects significantly.
The trial did not meet its primary endpoint or secondary endpoint, and Oramed confirmed that it “expects to discontinue” its oral insulin clinical activities for type 2 diabetes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze